MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said a patent had been granted protecting its unique system used to deliver a cannabis-derived drug being developed to combat hard-to-treat forms of epilepsy.
The Slovenian Intellectual Property Office has provided sign-off for CannEpil, which uses a self-nano emulsifying technology to carry the company’s high CBD, low THC medicinal compound.
“We are very pleased that the patent for our proprietary drug delivery system has now been granted by the Slovenian Intellectual Property Office,” said MGC’s managing director and co-founder, Roby Zomer.
“This is a recognition of the strength of our product and provides legal commercial protection for our company and our partner's IP.”
CannEpil is one of four products approved for use in the Republic of Ireland and prescribed to 300-400 people both in the Republic and Australia.
Epilepsy affects around 600,000 people in the UK and 50mln worldwide.
A third of adults and up to a quarter of children suffer the refractory, or hard-to-treat form of the condition targeted by CannEpil.